Opioid REMS: Sponsors Share Implementation, But Also Give Up Some Control
Executive Summary
Now that FDA has unveiled what it expects in a Risk Evaluation and Mitigation Strategy for long-acting and extended-release opioids, sponsors will be scrambling to write the REMS for their individual products and put together the shared components and implementation system envisioned by the agency.
You may also be interested in...
FDA Standardizing REMS Re-Enrollment Procedures
Common registration site for participants in REMS was endorsed by several panel members during a joint meeting of the Drug Safety and Risk Management and Dermatologic and Ophthalmic Drugs Advisory Committees.
Opioid Class-Wide REMS May Launch Without Element To Monitor Prescribing
All metrics for assessing the effectiveness of the Risk Evaluation and Mitigation Strategy for long-acting/extended release opioids may not be in place when FDA approves REMS for individual products.
Opioid Class-Wide REMS May Launch Without Element To Monitor Prescribing
All metrics for assessing the effectiveness of the Risk Evaluation and Mitigation Strategy for long-acting/extended release opioids may not be in place when FDA approves REMS for individual products.